Company Description
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities.
It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin’s lymphoma.
It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
| Country | United States |
| Founded | 2013 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 239 |
| CEO | Vladimir Coric |
Contact Details
Address: 215 Church Street New Haven, Connecticut 06510 United States | |
| Phone | 203 404 0410 |
| Website | biohaven.com |
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001935979 |
| CUSIP Number | G11196105 |
| ISIN Number | VGG1110E1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman and Chief Executive Officer |
| Matthew Buten | Chief Financial Officer |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
| Deb Young | Director of Regulatory Affairs and Operations |
| George C. Clark | Vice President and Chief Accounting Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| Warren Volles J.D. | General Counsel and Chief Legal Officer |
| Clifford Bechtold M.S. | President, GM of Biohaven Ireland and Chief Compliance Officer |
| John Tilton | Chief Commercial Officer of Rare Diseases |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | CT ORDER | Filing |
| Oct 2, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 424B5 | Filing |
| Sep 30, 2024 | 424B5 | Filing |
| Sep 23, 2024 | 8-K | Current Report |